Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences

被引:24
|
作者
Noparatayaporn, Prapaporn [1 ,2 ]
Thavorncharoensap, Montarat [1 ,3 ]
Chaikledkaew, Usa [1 ,3 ]
Bagepally, Bhavani Shankara [4 ]
Thakkinstian, Ammarin [1 ,5 ]
机构
[1] Mahidol Univ Hlth Technol Assessment MUHTA Grad P, Bangkok, Thailand
[2] Mahidol Univ, Fac Med, Dept Pharm, Siriraj Hosp, Bangkok, Thailand
[3] Mahidol Univ, Social & Adm Pharm Div, Dept Pharm, Fac Pharm, 447 Sri Ayudhaya Rd, Bangkok 10400, Thailand
[4] ICMR Natl Inst Epidemiol, Chennai, Tamil Nadu, India
[5] Mahidol Univ, Fac Med, Dept Clin Epidemiol & Biostat, Ramathibodi Hosp, Bangkok, Thailand
基金
比尔及梅琳达.盖茨基金会;
关键词
Incremental net monetary benefit; Cost-effectiveness; Bariatric surgery; Economic evaluation;
D O I
10.1007/s11695-021-05415-9
中图分类号
R61 [外科手术学];
学科分类号
摘要
This systematic review aimed to comprehensively synthesize cost-effectiveness evidences of bariatric surgery by pooling incremental net monetary benefits (INB). Twenty-eight full economic evaluation studies comparing bariatric surgery with usual care were identified from five databases. In high-income countries (HICs), bariatric surgery was cost-effective among mixed obesity group (i.e., obesity with/without diabetes) over a 10-year time horizon (pooled INB = $53,063.69; 95% CI $42,647.96, $63,479.43) and lifetime horizon (pooled INB = $101,897.96; 95% CI $79,390.93, $124,404.99). All studies conducted among obese with diabetes reported that bariatric surgery was cost-effective. Also, the pooled INB for obesity with diabetes group over lifetime horizon in HICs was $80,826.28 (95% CI $32,500.75, $129,151.81). Nevertheless, no evidence is available in low- and middle-income countries.
引用
收藏
页码:3279 / 3290
页数:12
相关论文
共 50 条
  • [1] Incremental Net Monetary Benefit of Bariatric Surgery: Systematic Review and Meta-Analysis of Cost-Effectiveness Evidences
    Prapaporn Noparatayaporn
    Montarat Thavorncharoensap
    Usa Chaikledkaew
    Bhavani Shankara Bagepally
    Ammarin Thakkinstian
    [J]. Obesity Surgery, 2021, 31 : 3279 - 3290
  • [2] Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence
    Udayachalerm, Sariya
    Renouard, Maranda G.
    Anothaisintawee, Thunyarat
    Thakkinstian, Ammarin
    Veettil, Sajesh K.
    Chaiyakunapruk, Nathorn
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 26 - 37
  • [3] Incremental Net Benefit and Incremental Cost-Effectiveness Ratio of COVID-19 Vaccination Campaigns: Systematic Review of Cost-Effectiveness Evidence
    Santoli, Giuseppe
    Nurchis, Mario Cesare
    Calabro, Giovanna Elisa
    Damiani, Gianfranco
    [J]. VACCINES, 2023, 11 (02)
  • [4] Incremental net benefit of whole genome sequencing for newborns and children with suspected genetic disorders: Systematic review and meta-analysis of cost-effectiveness evidence
    Nurchis, Mario Cesare
    Riccardi, Maria Teresa
    Radio, Francesca Clementina
    Chillemi, Giovanni
    Bertini, Enrico Silvio
    Tartaglia, Marco
    Cicchetti, Americo
    Dallapiccola, Bruno
    Damiani, Gianfranco
    [J]. HEALTH POLICY, 2022, 126 (04) : 337 - 345
  • [5] Effectiveness and cost-effectiveness of paediatric bariatric surgery: a systematic review
    Aikenhead, A.
    Knai, C.
    Lobstein, T.
    [J]. CLINICAL OBESITY, 2011, 1 (01) : 12 - 25
  • [6] The results of a pharmacoeconomic study: incremental cost-effectiveness ratio versus net monetary benefit
    Messori, Andrea
    Trippoli, Sabrina
    [J]. HEART, 2017, 103 (21) : 1746 - 1746
  • [7] Incremental net monetary benefit of using varenicline for smoking cessation: A systematic review and meta-analysis of economic evaluation studies
    Chaisai, Chayutthaphong
    Patikorn, Chanthawat
    Thavorn, Kednapa
    Lee, Shaun Wen Huey
    Chaiyakunapruk, Nathorn
    Veettil, Sajesh K.
    [J]. ADDICTION, 2024, 119 (07) : 1188 - 1202
  • [8] Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives
    Trippoli, Sabrina
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2017, 43 : E36 - E36
  • [9] Systematic review and meta-analysis of incremental cost-effectiveness ratio (ICER) for new cancer drugs.
    Oliveira, Fernanda Alves
    Oliveira, Eduardo Alves
    Lopes, Gilberto
    Lima, Joao Paulo S. N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [10] Does Cost-Effectiveness Analysis Really Need to Abandon the Incremental Cost-Effectiveness Ratio to Embrace Net Benefit?
    O'Mahony, James F.
    [J]. PHARMACOECONOMICS, 2020, 38 (08) : 777 - 779